Literature DB >> 2504598

Antimicrobial activity and interaction of pefloxacin and its principal metabolites. Collaborative Antimicrobial Susceptibility Testing Group.

R N Jones1.   

Abstract

The in vitro antimicrobial activity of pefloxacin and its major metabolites was determined and the interaction of pefloxacin and N-demethyl pefloxacin (norfloxacin) assessed at the ratio naturally occurring in urine (1:2). Pefloxacin and N-demethyl pefloxacin had approximately the same spectrum but were markedly more active than N-oxide pefloxacin (MIC90s greater than or equal to 64 micrograms/ml) against 867 stock strains. When combined with N-demethyl pefloxacin, pefloxacin had greater potency and a broader spectrum in tests against 5869 fresh clinical organisms. For approximately 10% more strains pefloxacin MICs were less than or equal to 2 micrograms/ml when pefloxacin was combined with 2 parts (4 micrograms/ml) of N-demethyl pefloxacin. The most significant extension of the pefloxacin spectrum was to include non-enteric gram-negative bacilli (inhibition of 67% versus 88%) and enterococci-streptococci (inhibition of 33% versus 86%). These results are similar to those previously noted for enoxacin plus 3-oxo-enoxacin, and potentially achievable with other newer fluoro-quinolones undergoing significant metabolism.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504598     DOI: 10.1007/bf01967479

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  In-vitro antimicrobial activity of enoxacin and its metabolites.

Authors:  R M Jones
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

3.  Pharmacokinetics of pefloxacin in normal and impaired renal function.

Authors:  D Höffler; I Schäfer; P Koeppe; F Sörgel
Journal:  Arzneimittelforschung       Date:  1988-05

4.  Pefloxacin in the treatment of nosocomial lower respiratory tract infections in intensive care patients.

Authors:  C Martin; F Gouin; F Fourrier; W Junginger; B L Prieur
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

5.  Difloxacin metabolism and pharmacokinetics in humans after single oral doses.

Authors:  G R Granneman; K M Snyder; V S Shu
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

6.  In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin).

Authors:  J B Cornett; R B Wagner; R A Dobson; M P Wentland; D M Bailey
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

7.  Bactericidal activity and killing rate of serum in volunteers receiving pefloxacin alone or in combination with ceftazidime, piperacillin or mezlocillin against Pseudomonas aeruginosa.

Authors:  P Van der Auwera; M Husson; J Klastersky
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

Review 8.  A review of cephalosporin metabolism: a lesson to be learned for future chemotherapy.

Authors:  R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jan-Feb       Impact factor: 2.803

  8 in total
  1 in total

1.  In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination against Legionella species.

Authors:  R N Jones; M E Erwin; M S Barrett
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.